COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME
Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid in an acid or a salt form, or in a molecular complex can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
1 . A method of treating complex regional pain syndrome comprising orally administering a dosage form comprising zoledronic acid in an acid or a salt form, and a lysine, to a human being in need thereof, wherein the human being receives about 400 to about 500 mg of zoledronic acid or a salt thereof within a period of six months.
2 . The method of claim 1 , wherein the lysine is DL-lysine.
3 . The method of claim 1 , wherein the dosage form contains about 150 mg to about 170 mg of zoledronic acid.
4 . The method of claim 2 , wherein the dosage form contains about 150 mg to about 170 mg of zoledronic acid.
5 . The method of claim 1 , wherein the zoledronic acid is orally administered 2 to 5 times in a month.
6 . The method of claim 4 , wherein the zoledronic acid is orally administered 2 to 5 times in a month.
7 . The method of claim 1 , wherein a total of about 450 mg to about 500 mg of the zoledronic acid is administered.
8 . The method of claim 6 , wherein a total of about 450 mg to about 500 mg of the zoledronic acid is administered.
9 . The method of claim 1 , wherein two or three doses of about 100 mg to about 150 mg of the zoledronic acid are orally administered within a period of two months.
10 . The method of claim 2 , wherein two or three doses of about 100 mg to about 150 mg of the zoledronic acid are orally administered within a period of two months.
11 . The method of claim 1 , wherein two doses of about 200 mg to about 250 mg of the zoledronic acid are orally administered within a period of two months.
12 . The method of claim 2 , wherein two doses of about 200 mg to about 250 mg of the zoledronic acid are orally administered within a period of two months.
13 . The method of claim 1 , wherein the human being experiences pain relief for at least 48 hours.
14 . The method of claim 1 , wherein at least some of the zoledronic acid is in a salt form.
15 . The method of claim 1 , wherein the zoledronic acid is administered in a dosage form and the dosage form further comprises water.
16 . The method of claim 1 , wherein the zoledronic acid is administered in a dosage form and the dosage form further comprises magnesium stearate.
17 . The method of claim 1 , wherein the zoledronic acid and the lysine are present in a solid having X-ray powder diffraction peaks at about 9.1° 2↓, about 14.7° 2θ, about 18.0° 2θ, about 21.2° 2θ, and about 26.0° 2θ.
18 . The method of claim 1 , wherein the zoledronic acid and the lysine are present in a solid having X-ray powder diffraction peaks at about 8.8° 2θ, about 9.7° 2θ, about 17.6° 2θ, about 23.1° 2θ, and about 26.5° 2θ.
19 . The method of claim 1 , wherein the zoledronic acid and the lysine are present in a solid having X-ray powder diffraction peaks at about 8.3° 2θ, about 11.8° 2θ, about 12.3° 2θ, about 15.8° 2θ, and about 20.8° 2θ.
20 . The method of claim 1 , wherein the zoledronic acid and the lysine are present in a solid having X-ray powder diffraction peaks at about 9.7° 2θ, about 10.8° 2θ, about 14.4° 2θ, about 18.9° 2θ, and about 21.4° 2θ.
21 . The method of claim 1 , wherein the zoledronic acid and the lysine are present in a solid having X-ray powder diffraction peaks at 7.2° 2θ, about 14.0° 2θ, about 18.3° 2θ, about 19.1° 2θ, about 20.7° 2θ, about 24.6° 2θ, and about 34.4° 2θ.
22 . The method of claim 1 , wherein the zoledronic acid and the lysine are present in a solid having X-ray powder diffraction peaks at 6.6° 2θ, about 11.0° 2θ, about 14.2° 2θ, about 18.3° 2θ, about 19.7° 2θ, about 22.7° 2θ, and about 27.6° 2θ.
23 . The method of claim 1 , wherein the zoledronic acid and the lysine are present in a solid having X-ray powder diffraction peaks at about 9.0° 2θ, about 14.4° 2θ, about 18.1° 2θ, about 26.0° 2θ, and about 29.6° 2θ.
24 . The method of claim 1 , wherein the zoledronic acid and the lysine are present in a solid having X-ray powder diffraction peaks at about 9.6° 2θ, about 10.7° 2θ, about 14.3° 2θ, about 21.4° 2θ, and about 23.5° 2θ.
25 . The method of claim 8 , wherein the zoledronic acid and the lysine are present in a solid having X-ray powder diffraction peaks at about 9.1° 2θ, about 14.7° 2θ, about 18.0° 2θ, about 21.2° 2θ, and about 26.0° 2θ.
26 . The method of claim 8 , wherein the zoledronic acid and the lysine are present in a solid having X-ray powder diffraction peaks at about 8.8° 2θ, about 9.7° 2θ, about 17.6° 2θ, about 23.1° 2θ, and about 26.5° 2θ.
27 . The method of claim 8 , wherein the zoledronic acid and the lysine are present in a solid having X-ray powder diffraction peaks at about 8.3° 2θ, about 11.8° 2θ, about 12.3° 2θ, about 15.8° 2θ, and about 20.8° 2θ.
28 . The method of claim 8 , wherein the zoledronic acid and the lysine are present in a solid having X-ray powder diffraction peaks at about 9.7° 2θ, about 10.8° 2θ, about 14.4° 2θ, about 18.9° 2θ, and about 21.4° 2θ.
29 . The method of claim 8 , wherein the zoledronic acid and the lysine are present in a solid having X-ray powder diffraction peaks at 7.2° 2θ, about 14.0° 2θ, about 18.3° 2θ, about 19.1° 2θ, about 20.7° 2θ, about 24.6° 2θ, and about 34.4° 2θ.
30 . The method of claim 8 , wherein the zoledronic acid and the lysine are present in a solid having X-ray powder diffraction peaks at 6.6° 2θ, about 11.0° 2θ, about 14.2° 2θ, about 18.3° 2θ, about 19.7° 2θ, about 22.7° 2θ, and about 27.6° 2θ.